ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation

被引：0
|
作者：
Bengtsson, Karin Lovgren [1 ]
Morein, Bror [2 ]
Osterhaus, Albert D. M. E. [3 ,4 ]
机构：
[1] Isconova AB, SE-75318 Uppsala, Sweden
[2] Uppsala Univ, Dept Med Sci, Virol Sect, Uppsala, Sweden
[3] Erasmus MC, Dept Virol, Rotterdam, Netherlands
[4] ViroClin Biosci BV, Rotterdam, Netherlands
来源：
EXPERT REVIEW OF VACCINES | 2011年 / 10卷 / 04期
关键词：
ISCOM; Matrix M; Quillaja saponaria Molina; saponin; Th1/Th2; vaccine adjuvant; IMMUNOSTIMULATING COMPLEXES; PROTEIN; SAFETY;
D O I：
10.1586/ERV.11.25
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：401 / 403
页数：3
相关论文
共 3 条
  • [1] The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century
    Stertman, Linda
    Palm, Anna-Karin E.
    Zarnegar, Behdad
    Carow, Berit
    Andersson, Carolina Lunderius
    Magnusson, Sofia E.
    Carnrot, Cecilia
    Shinde, Vivek
    Smith, Gale
    Glenn, Gregory
    Fries, Louis
    Bengtsson, Karin Loevgren
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (01)
  • [2] Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
    Magnusson, Sofia E.
    Altenburg, Arwen F.
    Bengtsson, Karin Lovgren
    Bosman, Fons
    de Vries, Rory D.
    Rimmelzwaan, Guus F.
    Stertman, Linda
    IMMUNOLOGIC RESEARCH, 2018, 66 (02) : 224 - 233
  • [3] Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology
    Atsmon, Jacob
    Heffetz, Daphna
    Deutsch, Lisa
    Deutsch, Frederic
    Sacks, Hagit
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (07): : 751 - 758
1